84659-98-3 Usage
Uses
Used in Pharmaceutical Industry:
6-hydroxy-2-phenylpyrimidine-4-carboxylic acid is used as a potential anti-inflammatory agent for its ability to modulate inflammatory responses and alleviate symptoms associated with inflammation.
6-hydroxy-2-phenylpyrimidine-4-carboxylic acid is also used as a potential antioxidant agent for its capacity to neutralize free radicals and protect cells from oxidative damage, which can contribute to various diseases and aging processes.
Used in Drug Development:
6-hydroxy-2-phenylpyrimidine-4-carboxylic acid serves as a chemical scaffold for the development of new drugs targeting specific biological pathways or receptors, given its unique chemical structure and functional groups that can be further modified to enhance its therapeutic effects.
Check Digit Verification of cas no
The CAS Registry Mumber 84659-98-3 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 8,4,6,5 and 9 respectively; the second part has 2 digits, 9 and 8 respectively.
Calculate Digit Verification of CAS Registry Number 84659-98:
(7*8)+(6*4)+(5*6)+(4*5)+(3*9)+(2*9)+(1*8)=183
183 % 10 = 3
So 84659-98-3 is a valid CAS Registry Number.
84659-98-3Relevant academic research and scientific papers
HETEROCYCLIC COMPOUND
-
Paragraph 0506, (2016/09/26)
The problem of the present invention is to provide a compound having a PDE2A inhibitory action, and useful as a prophylactic or therapeutic drug for schizophrenia, Alzheimer's disease and the like. The present invention relates to a compound represented by the formula (I): wherein each symbol is as described in the DESCRIPTION, or a salt thereof.
SOLUBILIZED THIAZOLOPYRIDINES
-
Page/Page column 66-67, (2009/06/27)
Provided herein are novel sirtuin-modulating compounds Structural Formula (I): and methods of use thereof. The sirtuin-modulating compounds may be used for increasing the lifespan of a cell, and treating and/or preventing a wide variety of diseases and disorders including, for example, diseases or disorders related to aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood clotting disorders, inflammation, cancer, and/or flushing as well as diseases or disorders that would benfit from increased mitochondrial activity. Also provided are compositions comprising a sirtuin-modulating compound in combination with another therapeutic agent.
